Literature DB >> 10484969

Olanzapine-induced elevation of plasma triglyceride levels.

B B Sheitman, P M Bird, W Binz, L Akinli, C Sanchez.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10484969

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  18 in total

1.  Are African American patients at a higher risk for olanzapine-induced glucose intolerance?

Authors:  J Ananth; S Gunatilake; S Aquino; V Bach; J Costa
Journal:  Psychopharmacology (Berl)       Date:  2001-09       Impact factor: 4.530

Review 2.  Metabolic consequences of atypical antipsychotic drugs.

Authors:  Harold E Lebovitz
Journal:  Psychiatr Q       Date:  2003

3.  Olanzapine metabolic side effects: a weight gain issue?

Authors:  Lucia Carulli; Fausto Mazzi; Stefania Rondinella; Marco Bertolotti
Journal:  Intern Emerg Med       Date:  2008-03-28       Impact factor: 3.397

Review 4.  Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?

Authors:  David C Henderson
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 5.  Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Authors:  John W Newcomer
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 6.  Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis.

Authors:  Salvatore Gentile
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 7.  First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

Authors:  Deanna L Kelly; Robert R Conley; William T Carpenter
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 8.  Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents.

Authors:  David C Henderson
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

Review 9.  [Diabetes mellitus as a complication of treatment with atypical neuroleptics. Possible pathomechanisms and treatment recommendations].

Authors:  H Jahn; T Schneider
Journal:  Nervenarzt       Date:  2004-05       Impact factor: 1.214

10.  Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

Authors:  David C Henderson; Xiaoduo Fan; Paul M Copeland; Bikash Sharma; Christina P Borba; Ryan Boxill; Oliver Freudenreich; Corinne Cather; A Eden Evins; Donald C Goff
Journal:  J Clin Psychopharmacol       Date:  2009-04       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.